Skip to main content
Scientists struggle to keep up with demand for CAR T therapy

Oncologists and research labs are struggling to keep up with demand for chimeric antigen receptor T-cell therapy as more clinical trials get underway and desperately ill patients seek access to the promising therapy. The investigational approach, which involves the time-consuming and expensive process of genetically engineering autologous immune cells, is risky but has shown strong results, especially in patients with lymphoma.

Full Story: